HER2+VE Breast Cancer By Amish Vora
SESSION 2 : HER2+VE BREAST CANCER
Chairpersons :
Avinash Deo, Vivek Agarwala, Amul Kapoor
Reviewer :
Amish Vora
1. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results
of the phase III multicentric italian short-HER study
Author: Pier Franco Conte
Citation: Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 501-501.ASCO
Abstract 501
2. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks
versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early
HER2- positive breast cancer (the SOLD study)
Author: Joensuu H.
Citation: SABCS Abstract GS3-04